NCCN Breast Cancer Guidelines* Elevate the Oncotype DX Breast Recurrence Score
The only preferred multi-gene test to determine chemotherapy benefit
*NCCN and NCCN Guidelines are trademarks of the National Comprehensive Cancer Network. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed [October 5, 2018]. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN does not endorse any product or therapy.
When Amy was diagnosed with breast cancer, she was scared. Her Oncotype DX Breast DCIS Score result made her feel in control.
How much do ineffective cancer treatments cost the healthcare system? In the US alone, Oncotype IQ tests have saved more than $3.5 billion.
The Eighth Edition AJCC Staging Manual is now effect, and it has changed staging for T1-2 N0 M0 breast cancer patients.
Latest TAILORx Data
The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.
Sign up for Our Healthcare Professional Updates